Written by Ben Adams
The Dana-Farber Cancer Institute is getting into the life science funding biz with the launch of its venture arm Binney Street Capital.
Dana-Farber is certainly no stranger to backing biotechs and teaming up with other VCs; …
Written by Jessica Bartlett
One of the nation’s largest physician groups is in the works to acquire the state’s largest independent doctor group, a decision that would further cement the national group’s presence in Massachusetts.
Optum, the for-profit health provider …
Written by Nick Paul Taylor
Bluebird bio is planning to spin off its oncology assets into a new publicly traded company. The move follows a series of operational missteps that have delayed patient access to once-hyped therapies.
Today, bluebird’s pipeline …
Written by Jessica Bartlett
Haven, the health care startup launched by Amazon, Berkshire Hathaway, and JPMorgan Chase & Co. three years ago with much fanfare, announced on Monday that it would disband, leaving the three companies to solve the problems …
Written by Angus Liu
Just when Gilead Sciences’ $21 billion acquisition of Immunomedics looked to be 2020’s biggest biopharma deal, AstraZeneca came up with an even larger one—and it involves one of the industry’s top takeover targets.
AstraZeneca is splashing out $39 …
